HC Wainwright reissued their buy rating on shares of Verastem (NASDAQ:VSTM – Free Report) in a report issued on Tuesday morning, Benzinga reports. The brokerage currently has a $17.50 target price on the biopharmaceutical company’s stock. A number of other research firms also recently commented on VSTM. Royal Bank of Canada reaffirmed an outperform rating […]